Teachers Retirement System of The State of Kentucky Acquires 4,508 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Teachers Retirement System of The State of Kentucky boosted its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRSGet Rating) by 7.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 66,814 shares of the biotechnology company’s stock after purchasing an additional 4,508 shares during the quarter. Teachers Retirement System of The State of Kentucky owned about 0.10% of Aclaris Therapeutics worth $1,152,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. BNP Paribas Arbitrage SA grew its holdings in Aclaris Therapeutics by 20.2% during the 4th quarter. BNP Paribas Arbitrage SA now owns 10,852 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,823 shares in the last quarter. Ensign Peak Advisors Inc purchased a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $160,000. Blair William & Co. IL grew its holdings in Aclaris Therapeutics by 27.4% during the 4th quarter. Blair William & Co. IL now owns 12,800 shares of the biotechnology company’s stock valued at $186,000 after buying an additional 2,750 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in Aclaris Therapeutics by 64.3% during the 4th quarter. Point72 Asset Management L.P. now owns 642,900 shares of the biotechnology company’s stock valued at $9,348,000 after buying an additional 251,600 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $26,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald restated an “overweight” rating on shares of Aclaris Therapeutics in a report on Monday, August 1st. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $38.00.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $13.85 on Friday. The stock has a market cap of $923.41 million, a price-to-earnings ratio of -10.34 and a beta of 0.59. The stock has a 50 day moving average price of $15.99 and a 200-day moving average price of $15.16. Aclaris Therapeutics, Inc. has a one year low of $9.26 and a one year high of $19.97.

Aclaris Therapeutics (NASDAQ:ACRSGet Rating) last announced its earnings results on Wednesday, August 3rd. The biotechnology company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05. The firm had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $1.59 million. Aclaris Therapeutics had a negative return on equity of 40.14% and a negative net margin of 1,355.98%. Sell-side analysts predict that Aclaris Therapeutics, Inc. will post -1.47 earnings per share for the current fiscal year.

Aclaris Therapeutics Profile

(Get Rating)

Aclaris Therapeutics, Inc operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases.

Featured Stories

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.